Gliomas Clinical Trial
Official title:
The Application of ZOOMit-fMRI to Identify Motor Functional Cortex
This study was designed to collect a series of patients with gliomas which were involved in motor cortex to analyze difference accuracy of motor cortex localization between BOLD-fMRI and ZOOMit-fMRI.
Gliomas will lead motor dysfunction when they are involved in motor cortex. However, tumor
resection also have risk to lead postoperatively motor function deficits if destroy patients'
motor cortex when tumor removed. Hence, it is important for neurosurgeon to realize the
situation of patients' motor cortex locations in order to determine personal operative
protocol.
The blood oxygen level dependent fMRI (BOLD-fMRI) is a prevalent preoperative method to
localization motor cortex. It shows motor relevant cortex by the change of blood oxygen level
when patients cooperate to finish motor tasks. The advantage of BOLD-fMRI includes higher
time and spatial resolution, higher sensitivity, non-invasive. However, its accuracy of
localization has not been satisfactory because neurovascular uncoupling. The ZOOMit-fMRI is a
novel technic which is evolved from conventional BOLD-fMRI to localize motor functional
cortex.The advantage of ZOOMit-fMRI is smaller field of view (FOV) and higher spatial
resolution comparing with BOLD-fMRI. That helps to reduce other region of brain interference
and elevate accuracy of localizations.
In this study, the investigators plan to enroll 60 patients, whose gliomas are involved in
motor cortex, to acquire their BOLD-fMRI and ZOOMit-fMRI data in order to analyze their
difference in the accuracy of motor cortex localization.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03952598 -
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
|
N/A | |
| Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
| Terminated |
NCT01251913 -
A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes
|
||
| Withdrawn |
NCT01961934 -
C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03557359 -
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
|
Phase 2 | |
| Recruiting |
NCT01655927 -
Efficacy of Tranexamic Acid in Brain Tumor Resections
|
Phase 3 | |
| Completed |
NCT01144247 -
Cellular Immunotherapy Study for Brain Cancer
|
Phase 1 | |
| Completed |
NCT01225003 -
Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas
|
N/A | |
| Completed |
NCT00967577 -
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
|
Phase 1 | |
| Terminated |
NCT01517776 -
Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents
|
Phase 2 | |
| Completed |
NCT00832598 -
[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors
|
N/A | |
| Completed |
NCT00589706 -
A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas
|
Phase 2 | |
| Completed |
NCT03154996 -
Chronic Convection Enhanced Delivery of Topotecan
|
Phase 1 | |
| Withdrawn |
NCT05054400 -
Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR
|
Early Phase 1 | |
| Completed |
NCT00200161 -
Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma
|
Phase 2 | |
| Terminated |
NCT02332889 -
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05804227 -
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults
|
Early Phase 1 |